目的 :观察扎鲁司特对哮喘的临床疗效。方法 :176例非急性发作期哮喘病人均给扎鲁司特2 0mg ,po ,bid ,疗程 6wk。观察临床疗效、肺功能变化和不良反应。结果 :1秒钟用力呼气量(FEV1)、呼气流量峰值 (PEF)治疗后wk 2 ,4 ,6末与治疗前比较 ,差异均有非常显著意义 (P <0 .0 1) ;其中轻度组和中度组早晨PEF增加较重度组更为显著 (P <0 .0 5 ) ,轻度组和中度组PEF日内波动率较重度组下降更为显著 (P <0 .0 1)。治疗后 ,临床控制 5 0例 (2 8.4 % ) ,显著改善 92例 (5 2 .3% ) ,改善 2 5例 (14.2 % ) ,无效 9例 (5 .1% ) ,其中轻度组和中度组疗效较重度组更佳 (P <0 .0 5 ) ,激素低敏感型 (SI)哮喘病人临床有效率达 10 0 %。未见严重不良反应。结论 :扎鲁司特对哮喘是一种新型的、安全、有效的抗炎和平喘药物 Objective: To observe the clinical efficacy of zafirlukast on asthma. Methods: 176 cases of non-acute exacerbation asthma patients were given zafirlukast 20mg, po, bid, course of treatment 6wk. To observe the clinical efficacy, changes in lung function and adverse reactions. Results: FEV1 and peak expiratory flow (PEF) at the end of wk 2, 4 and 6 were significantly different from those before treatment (P <0.01) In the mild group and the moderate group, the PEF increased more significantly in the severe group (P <0.05), and the intra-day fluctuation of the PEF in the mild group and the moderate group was more significant (P <0.01) ). After treatment, 50 cases (2 8.4%) were clinically controlled, 92 cases (52.3%) were significantly improved, 25 cases (14.2%) were improved and 9 cases (5.1%) were ineffective. The moderate group was more effective than the severe group (P <0.05), and the clinically effective rate of the hormone-hypo-allergenic (SI) asthma was 100%. No serious adverse reactions. Conclusions: Zafirlukast is a novel, safe and effective anti-inflammatory and antiasthmatic agent for asthma